• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Opthea Limited

    11/10/25 8:50:35 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OPT alert in real time by email
    S-8 POS 1 d26088ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on November 10, 2025

    Registration No. 333-251052

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    OPTHEA LIMITED

    (Exact name of registrant as specified in its charter)

     

     

     

    Australia   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    C/- Prime Company Compliance, Level 9

    505 Little Collins Street

    Melbourne, VIC 3000

    Australia

    + 61 3 9826 0399

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Opthea Limited –Long-Term Incentive Plan

    Opthea Limited – Non-Executive Director Share and Option Plan

    (Full title of the plans)

    Corporation Service Company

    19 West 44th Street, Suite 200

    New York, New York 10036

    (800) 927-9800

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☐
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

    Copies to:

    Ferish Patel

    Milson Yu

    Cooley LLP

    182 Cecil Street, Level 38

    Frasers Tower

    Singapore 069547

    +65 6962-7500

     

     
     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the Registration Statement on Form S-8 (File No. 333-251052) (the “Registration Statement”) of Opthea Limited (“Registrant”), filed with the Securities Exchange Commission (the “SEC”) on December 1, 2020.

    The Registrant is filing this Post-Effective Amendment to deregister any and all securities that remain unsold or otherwise unissued under the Registration Statement as of the date hereof. By filing this Post-Effective Amendment, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. Accordingly, the Registrant hereby terminates the effectiveness of the Registration Statement and, in accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold or otherwise unissued at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold or otherwise unissued as of the date hereof.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No.1 to the Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on November 10, 2025.

     

    OPTHEA LIMITED
    By:  

    /s/ Jeremy Levin, D.Phil, MB BChir

    Name:   Jeremy Levin, D.Phil, MB BChir
    Title:   Chief Executive Officer

     

    II-1


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Opthea Limited, has signed this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 on November 10, 2025.

     

    PUGLISI & ASSOCIATES
    By:  

    /s/ Donald J. Puglisi

      Name: Donald J. Puglisi
      Title: Managing Director

     

    II-2

    Get the next $OPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPT

    DatePrice TargetRatingAnalyst
    3/25/2025$2.00Buy → Neutral
    H.C. Wainwright
    3/25/2025$12.00 → $1.00Outperform → Market Perform
    Leerink Partners
    3/25/2025$8.00 → $1.00Buy → Underperform
    Jefferies
    3/24/2025Outperform → Perform
    Oppenheimer
    12/8/2022$14.00Buy
    H.C. Wainwright
    4/26/2022$25.00Outperform
    SVB Leerink
    More analyst ratings

    $OPT
    SEC Filings

    View All

    SEC Form 15F-12B filed by Opthea Limited

    15F-12B - Opthea Ltd (0001815620) (Filer)

    11/20/25 4:05:18 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    11/20/25 4:02:11 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    11/12/25 8:30:53 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Opthea Ltd. downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Opthea Ltd. from Buy to Neutral and set a new price target of $2.00

    3/25/25 8:30:12 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Opthea Ltd. from Outperform to Market Perform and set a new price target of $1.00 from $12.00 previously

    3/25/25 8:25:42 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Jefferies with a new price target

    Jefferies downgraded Opthea Ltd. from Buy to Underperform and set a new price target of $1.00 from $8.00 previously

    3/25/25 8:25:11 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opthea Provides Corporate Update

    Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under the DFA. DFA Settlement In March of 2025, after the primary endpoints were not met in both COAST and ShORe phase 3 clinical trials, Opthea

    8/18/25 7:00:00 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces Decision to Discontinue Wet AMD Trials

    ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i

    3/31/25 12:01:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces COAST Phase 3 Trial Topline Results

    COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD

    3/24/25 12:01:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    11/14/24 6:00:28 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    7/3/24 7:15:39 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/14/24 4:21:51 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Financials

    Live finance-specific insights

    View All

    Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

    MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'

    12/12/22 10:08:46 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Leadership Updates

    Live Leadership Updates

    View All

    Opthea Appoints Kathy Connell to Board of Directors

    Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

    11/15/24 7:00:48 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

    Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

    10/8/24 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

    MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

    7/17/24 7:15:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care